
Applied Genetic Technologies Corporation AGTC
Quarterly report 2022-Q3
added 11-21-2022
Applied Genetic Technologies Corporation Total Liabilities 2011-2026 | AGTC
Annual Total Liabilities Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.2 M | 41.2 M | 29.3 M | 13.5 M | 19.4 M | 32.6 M | 71.5 M | 4.64 M | 2.53 M | 1.36 M | 34.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.5 M | 1.36 M | 26.1 M |
Quarterly Total Liabilities Applied Genetic Technologies Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 39.7 M | 37.2 M | 40.2 M | 40.9 M | 40.9 M | 41.2 M | 41.2 M | 30.4 M | 29.4 M | 29.3 M | 29.3 M | 22.2 M | 16.7 M | 13.5 M | 13.5 M | 32.1 M | 38.4 M | 19.4 M | 19.4 M | 19.8 M | 23.6 M | 32.6 M | 32.6 M | 48 M | 58.9 M | 71.5 M | 71.5 M | 94.1 M | 113 M | 4.64 M | 4.64 M | 2.72 M | 3.24 M | 2.53 M | 2.53 M | - | 3.57 M | 3.57 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 113 M | 2.53 M | 31.6 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | ||
|
BioNTech SE
BNTX
|
2.76 B | $ 95.5 | -3.88 % | $ 27.2 B | ||
|
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
707 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.35 | 0.72 % | $ 3.7 B | ||
|
Galapagos NV
GLPG
|
171 M | $ 28.39 | -0.13 % | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
12.8 B | $ 8.27 | 0.49 % | $ 6.83 B | ||
|
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.5 | 5.42 % | $ 5.76 M | ||
|
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | ||
|
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | ||
|
InflaRx N.V.
IFRX
|
13.7 M | $ 1.97 | -7.51 % | $ 152 M | ||
|
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
243 M | $ 23.42 | -0.3 % | $ 2.98 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | ||
|
Innate Pharma S.A.
IPHA
|
151 M | $ 1.4 | -2.1 % | $ 235 M | ||
|
CRISPR Therapeutics AG
CRSP
|
343 M | $ 52.38 | -2.24 % | $ 4.71 B | ||
|
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.64 | 4.46 % | $ 436 M | ||
|
Inventiva S.A.
IVA
|
226 M | $ 5.42 | 2.85 % | $ 138 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | ||
|
Завод ДИОД
DIOD
|
195 M | - | - | - | ||
|
Фармсинтез
LIFE
|
1.04 B | - | - | - | ||
|
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M |